Scheduled Meetings

- **Breast Imaging Integration Committee** – Friday 11/15/13 – 12:00-2:00 PM (open to ECOG-ACRIN members and invited guests)
- **Breast Core Committee** – Friday 11/15/13 - 2:00-4:00 PM (open to ECOG-ACRIN members and invited guests)
- **General Session** – Friday 11/15/13 – 7:00-8:30 PM
  - Sylvia Adams, MD: TILS in Triple Negative Breast Cancer
- **ACRIN Breast Committee Miniretreat** – Saturday 11/16/13 - 8:00-10:00 AM (open to ECOG-ACRIN members and invited guests)
- **Breast Committee (Educational Session)** – Saturday 11/16/13 – 10:00 AM – 12 Noon (open to all meeting attendees)

**BREAST IMAGING INTEGRATION COMMITTEE** Friday 11/15/13 – 12:00-2:00 PM

- Agenda to be distributed by Dr. Mankoff

**BREAST CORE COMMITTEE AGENDA** – Friday 11/15/13 2:00-4:00 PM

2:00-2:05 AM Introduction and Meeting Objectives (Sparano)

2:05-2:40 AM Proposed Concepts

- 2:05-2:20 PM: Phase II adjuvant trial in low risk HER2+ disease (Ahn/Gluck)
- 2:20-2:45 PM – Response adapted neoadjuvant therapy in HER2+ disease therapy (Sparano/Miller/Mankoff)
- 2:45-3:00 PM - Functional Imaging with FES-PET in ER+ MBC (Linden/Mankoff)
- 3:00-3:15 PM - E2112 methylation substudy (Sukumar/Connolly)
- 3:15-3:25 PM
  - Adjuvant endocrine therapy in elderly (Sparano/Zellars)
  - Randomized phase II cyclophosphamide plus veliparib/placebo (Sparano/Andreopoulou)
  - Phase II BMN673 in BRCA mutation carriers (Sparano/Ganesan)

3:25–3:55 PM - Updates

- 3:25-3:35 PM: Piotr Kulecza, MD – PCO-RL Update
- 3:35-3:50 PM: E5103 GWAS, E1199 neuropathy SNP validation, neuropathy metaanalysis (Schneider)
- 3:50 PM: PrE0102 – revised oral care for mucositis (Sparano)

3:50 PM – 4:00 PM - Concluding remarks, summary of action items, and announcement (Sparano)

Studies in development discussed at prior meetings/conference calls - for informational purposes:

- **E2112** (Connolly/Miller) – Phase III exemestane + entinostat/placebo in advanced breast cancer – approved by ECOG Executive Review on 3/15/12, resubmitted to BCSC for 10/17/12 review after pending on phase II (E1112), approved, CIRB approval 11/1/13 – for activation by April 2014.
• **E4112 DCIS protocol** (Lehman and DCIS Working Group) – lumpectomy +/- MRI +/- RT (based on DCIS score) – submitted to DCP on 8/29/12, reviewed by BOLD Task Force 9/20/12 – first full protocol drafts submitted in October 2013 for review, pre-IDE application pending

• **E5112 Triple negative neoadjuvant** (Telli/Ford): Randomized phase II AC-paclitaxel vs. carbo/gem in TNBC, with HRD marker interaction – approved by executive committee 12/20/12, reviewed by BCSC 7/13, received pending, response for discussion at November 2013 BCSC meeting

• **E1113 Triple negative postneoadjuvant proposal** (Mayer/Arteaga) Phase III trial cisplatin vs. no therapy in residual TNBC after neoadjuvant chemotherapy – approved by executive committee 3/21/13, BCSC “preconcept review” favorable, for submission to December 2013 BCSC, pilot study by ECOG PCO in progress, and PCO-Nanostring collaboration in progress

• **E3112 HER2 neoadjuvant** (Andreopolou/Leyland-Jones/Mankoff) Randomized phase II TDM1 + pertuzumab +/- bevacizumab – approved by ECOG EC on 8/16/12, reviewed by BOLD TF on 9/19/12, submission to steering committee held pending Genentech commitment regarding drug supply date, and pending BETH results

**ACRIN BREAST COMMITTEE MINIRETREAT- Saturday 11/16/13 - 8:00-10:00 AM**

- Agenda to be distributed by Dr.Comstock

**BREAST COMMITTEE EDUCATIONAL SESSION AGENDA – Saturday 11/16/13**

**10:00 AM-12 Noon**

10:00 – 11:00 AM Immune Tolerance, Immunity, and Breast Cancer

- 10:00-10:20 AM – Sylva Adams, MD. NYU Cancer Institute: Tumor Infiltrating Lymphocytes and Prognosis in Cancer: An Evolving Story

- 10:20AM-10:50 AM- Xingxing Zang, PhD. Albert Einstein College of Medicine – The Role of the B7 Family in Immune Tolerance

- 10:50 AM-11:00 AM – Questions and Panel Discussion

11:00-11:30 AM – Review of open studies and studies in development (Sparano/Comstock)

- Open EA-coordinated studies
  - E2108 (Khan), E1Z11 (Stearns/Chang), PrE0102 (Kornblum)
  - EL1112: TAILORx, E5103 Late Relapse Amendments
  - A6694, A6698

- EA studies pending activation
  - E2112 (Connolly), E4112 (Lehman)

- EA studies in development
  - E3112 (Andreopolou), E5112 (Telli), E1113 (Mayer)
  - FES-PET in ER-positive metastatic breast cancer (Linden)
  - Response-adapted neoadjuvant HER2 therapy (Sparano)

- Endorsed studies
  - Systemic therapy: B43, B47 B49, S1007, S1207
  - Local therapy: Z11102, R1005, B51

11:30-12:00 Noon – MATCH Trial

- Review of trial design (Sparano)
- Cancer Research Advocate Committee (Smith/Katz)

12:00 Noon – Concluding Remarks and Announcement